Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 130 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AM and PM Placebo Clear all
Completed Phase 3 Interventional Results available

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics

NCT01147861
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK256073, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Anniston, Alabama • Miami, Florida • Miami Gardens, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

NCT01516346
View directory record Official record
Conditions
Heart Failure, Congestive Heart Failure
Interventions
Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine, Placebo
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Topiramate in Adolescents With Severe Obesity

NCT01859013
View directory record Official record
Conditions
Obesity, Morbid, Obesity, Weight Loss
Interventions
Topiramate, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112
View directory record Official record
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Not applicable Interventional

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

NCT03173781
View directory record Official record
Conditions
Parkinson's Disease
Interventions
droxidopa, Placebo
Drug
Lead sponsor
Colorado Springs Neurological Associates
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 2, 2026, 12:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth

NCT06721884
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions
Artemisia Annua Leaf, placebo
Dietary Supplement · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 2, 2026, 12:45 AM EDT
Recruiting Not applicable Interventional

This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.

NCT07764328
View directory record Official record
Conditions
Polycystic Ovarian Syndrome (PCOS)
Interventions
A dietary supplement powder for women, Placebo
Dietary Supplement
Lead sponsor
Mila Mend Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Not applicable Interventional Results available

Oxcarbazepine Versus Placebo in Childhood Autism

NCT00467753
View directory record Official record
Conditions
Autism
Interventions
Oxcarbazepine, Placebo/sugar pill
Drug · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

NCT04405245
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
Latanoprost ophthalmic solution, AKB-9778 4%, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
21
States / cities
Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

NCT03091920
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
IW-1973, Placebo
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
30 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 2, 2026, 12:45 AM EDT
Terminated Phase 2 Interventional Results available

Trial To Evaluate the Efficacy of Oral Salsalate in the Treatment of Older Adults With Unexplained Anemia

NCT01506726
View directory record Official record
Conditions
Anemia
Interventions
Salsalate, Placebo
Drug
Lead sponsor
Harvey Jay Cohen
Other
Eligibility
65 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Summerfield, Florida • Savannah, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 2, 2026, 12:45 AM EDT
Active, not recruiting Not applicable Interventional

Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis

NCT06932783
View directory record Official record
Conditions
Cirrhosis
Interventions
Transcutaneous Electrical Acustimulation (TEA), Sham Transcutaneous Electrical Acustimulation (TEA)
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

NCT01747629
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
35
States / cities
Costa Mesa, California • Encinitas, California • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

NCT01424813
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors

NCT02938780
View directory record Official record
Conditions
Breast Cancer Female
Interventions
placebo text message, nutrition physical activity text message
Other
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
20 Years to 75 Years · Female only
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 2, 2026, 12:45 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Efficacy and Safety of VDPHL01 in Males With AGA

NCT06724614
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01, Placebo
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 2, 2026, 12:45 AM EDT
Withdrawn Not applicable Interventional

Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy

NCT00986115
View directory record Official record
Conditions
Epilepsy
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT01451827
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan MR, Tolvaptan IR, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

NCT01786668
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Tofacitinib 2 mg, Tofacitinib 5 mg, Tofacitinib 10 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Indian Wells, California • Palm Desert, California • Clearwater, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hypoglycemia and Autonomic Nervous System Function-B

NCT03429946
View directory record Official record
Conditions
Hypoglycemia, Healthy
Interventions
Spironolactone, Placebo, Hypoglycemic Hyperinsulinemic Clamp, Euglycemic Hyperinsulinemic Clamp
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 2, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

NCT00528372
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Dapagliflozin placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
38
States / cities
Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 2, 2026, 12:45 AM EDT
Terminated Phase 2 Interventional Results available

N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD

NCT00539188
View directory record Official record
Conditions
Borderline Personality Disorder, Self-Injurious Behavior
Interventions
N-Acetylcysteine, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 2, 2026, 12:45 AM EDT